WO2002012434A3 - A global electronic medicine response profile testing network - Google Patents

A global electronic medicine response profile testing network Download PDF

Info

Publication number
WO2002012434A3
WO2002012434A3 PCT/GB2001/003624 GB0103624W WO0212434A3 WO 2002012434 A3 WO2002012434 A3 WO 2002012434A3 GB 0103624 W GB0103624 W GB 0103624W WO 0212434 A3 WO0212434 A3 WO 0212434A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
genotype
analysis
given
sample
Prior art date
Application number
PCT/GB2001/003624
Other languages
French (fr)
Other versions
WO2002012434A2 (en
Inventor
Claire Judith Allan
Dirk Erik Pollett
Original Assignee
Glaxo Group Ltd
Claire Judith Allan
Dirk Erik Pollett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Claire Judith Allan, Dirk Erik Pollett filed Critical Glaxo Group Ltd
Priority to US10/344,292 priority Critical patent/US20040029138A1/en
Priority to EP01956677A priority patent/EP1356412A2/en
Priority to AU2001278599A priority patent/AU2001278599A1/en
Publication of WO2002012434A2 publication Critical patent/WO2002012434A2/en
Publication of WO2002012434A3 publication Critical patent/WO2002012434A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The present invention relates to healthcare management and specifically to an Internet-facilitated method of improving and applying knowledge to how the genetic make-up of a person affects their response to drug therapy. More particularly, the invention provides a method of using biological markers for the development and prescribing of medicines, such method comprising the steps of obtaining a biological sample from a patient; delivering the sample to a centralized analysis and storage facility; genotyping the sample at the facility, electronically providing the genotype analysis back to said patient upon request by said patient or said patient's healthcare provider in order to enable said healthcare provider to form a judgement as to the most appropriate drug to administer to said patient in view of said patient's genotype; contemporaneously electronically providing the genotype analysis to a peer review body for data analysis and then transmitting such analyzed data to a database so as to enable discovery of one or more associations between a given genotype and a given response to a given drug.
PCT/GB2001/003624 2000-08-10 2001-08-09 A global electronic medicine response profile testing network WO2002012434A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/344,292 US20040029138A1 (en) 2000-08-10 2001-08-09 Global electronic medicine response profile testing network
EP01956677A EP1356412A2 (en) 2000-08-10 2001-08-09 A global electronic medicine response profile testing network
AU2001278599A AU2001278599A1 (en) 2000-08-10 2001-08-09 A global electronic medicine response profile testing network

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22414600P 2000-08-10 2000-08-10
US60/224,146 2000-08-10

Publications (2)

Publication Number Publication Date
WO2002012434A2 WO2002012434A2 (en) 2002-02-14
WO2002012434A3 true WO2002012434A3 (en) 2003-08-14

Family

ID=22839443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003624 WO2002012434A2 (en) 2000-08-10 2001-08-09 A global electronic medicine response profile testing network

Country Status (3)

Country Link
EP (1) EP1356412A2 (en)
AU (1) AU2001278599A1 (en)
WO (1) WO2002012434A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
US7337071B2 (en) * 2002-11-18 2008-02-26 Hitachi, Ltd. Information processing system using base sequence-related information
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
EP1599576B1 (en) * 2003-02-20 2016-04-27 Mayo Foundation For Medical Education And Research Methods for selecting antidepressant medications
US20060136143A1 (en) * 2004-12-17 2006-06-22 General Electric Company Personalized genetic-based analysis of medical conditions
EP3223182A1 (en) 2005-11-29 2017-09-27 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
WO2008043566A2 (en) * 2006-10-11 2008-04-17 Janssen Pharmaceutica N.V. Compositions and methods for treating and diagnosing irritable bowel syndrome

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023078A1 (en) * 1995-01-27 1996-08-01 Incyte Pharmaceuticals, Inc. Computer system storing and analyzing microbiological data
WO1998013783A1 (en) * 1996-09-27 1998-04-02 Azron, Incorporated Electronic medical records system
WO1998024212A1 (en) * 1996-11-29 1998-06-04 Micromedical Industries Limited Telemedicine system
US5827180A (en) * 1994-11-07 1998-10-27 Lifemasters Supported Selfcare Method and apparatus for a personal health network
US5935060A (en) * 1996-07-12 1999-08-10 First Opinion Corporation Computerized medical diagnostic and treatment advice system including list based processing
WO2000070556A2 (en) * 1999-05-19 2000-11-23 Whitehead Institute For Biomedical Research A method and relational database management system for storing, comparing, and displaying results produced by analyses of gene array data
WO2001016858A2 (en) * 1999-08-27 2001-03-08 Pluvita Corporation System and method for genomic and proteomic human disease assessment via expression profile comparison

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827180A (en) * 1994-11-07 1998-10-27 Lifemasters Supported Selfcare Method and apparatus for a personal health network
WO1996023078A1 (en) * 1995-01-27 1996-08-01 Incyte Pharmaceuticals, Inc. Computer system storing and analyzing microbiological data
US5935060A (en) * 1996-07-12 1999-08-10 First Opinion Corporation Computerized medical diagnostic and treatment advice system including list based processing
WO1998013783A1 (en) * 1996-09-27 1998-04-02 Azron, Incorporated Electronic medical records system
WO1998024212A1 (en) * 1996-11-29 1998-06-04 Micromedical Industries Limited Telemedicine system
WO2000070556A2 (en) * 1999-05-19 2000-11-23 Whitehead Institute For Biomedical Research A method and relational database management system for storing, comparing, and displaying results produced by analyses of gene array data
WO2001016858A2 (en) * 1999-08-27 2001-03-08 Pluvita Corporation System and method for genomic and proteomic human disease assessment via expression profile comparison

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOULD ROTHBERG B E ET AL: "INTEGRATING EXPRESSION-BASED DRUG RESPONSE AND SNP-BASED PHARMACOGENETIC STRATEGIES INTO A SINGLE COMPREHENSIVE PHARMACOGENOMICS PROGRAM", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 49, no. 1, January 2000 (2000-01-01), pages 54 - 64, XP000965758, ISSN: 0272-4391 *

Also Published As

Publication number Publication date
WO2002012434A2 (en) 2002-02-14
EP1356412A2 (en) 2003-10-29
AU2001278599A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
FitzHenry et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership
Purba et al. Increased number of vasopressin-and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression
Basch et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Ganz Quality of life and the patient with cancer. Individual and policy implications
Mash et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures
WO2001041037A3 (en) Cardiovascular healthcare management system and method
Polcin Issues in the treatment of dual diagnosis clients who have chronic mental illness.
Potter et al. Substance use histories in patients seeking treatment for controlled-release oxycodone dependence
US20190121935A1 (en) Phenotypic personalized medicine: adaptive optimization of patient-specific combination therapy
WO2003019455A3 (en) System, method and computer program for monitoring and managing medications
WO2002012434A3 (en) A global electronic medicine response profile testing network
CN108198633A (en) For the medical management system of Chronic Obstructive Pulmonary Disease
Barohn Standards of measurements in myasthenia gravis
Majercak Advancing pharmacist prescribing privileges: Is it time?
Alomi et al. Cost analysis of drug information services at the mental hospital in Saudi Arabia
Ganz Quality of life measures in cancer chemotherapy: methodology and implications
Maarse et al. The governance of quality management in Dutch health care: new developments and strategic challenges
Usman et al. Pharmacometrics: a new era of pharmacotherapy and drug development in low-and middle-income countries
Winkelmann REHADAT: The German information system on assistive devices
Vlak et al. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia
Horgan et al. The substance abuse treatment system: What does it look like and whom does it serve
Robles et al. Implementation of a clinic policy of client-regulated methadone dosing
Winzenborg et al. A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data
Reist Methadone maintenance treatment in British Columbia, 1996-2008: Analysis and recommendations
Wallace et al. Quality of care provided by board-certified versus non-board-certified psychiatrists and neurologists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001956677

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10344292

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001956677

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001956677

Country of ref document: EP